Metropolis Healthcare Q2 FY27 Earnings Call: Guides 16% Revenue Growth, First Price Hike in Two Years

Metropolis Healthcare Ltd held its Q2 FY27 earnings call on November 03, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Growth Step-Up With Margin Expansion, No Price Increase

• Q2 FY 2026-2027 revenue of Rs.497 Cr, +16% YoY — ahead of stated guidance, driven by 10% patient volume growth and ~11% test volume growth, with the balance from richer test mix and better realization; delivered with no price increase in FY 2026-2027.
• Q2 EBITDA of Rs.135 Cr, +24% YoY — margin expanded 180 bps YoY to 27.2%, ahead of the company's FY 2026-2027 guidance of 125-170 bps expansion; H1 FY 2026-2027 margin expanded 190 bps to 26.2%.
• Q2 PAT of Rs.75 Cr, +43% YoY — PAT margin expanded 290 bps to 15.2%, the highest PAT margin in the post-COVID period.
• H1 FY 2026-2027 revenue grew 16.2% — a step-up from the historical 12-13% organic pace to 15-16% over the last 4-6 quarters; management is optimistic of a similar growth and margin trajectory for the rest of FY 2026-2027.
• Balance sheet strengthened — net working capital days improved to 13 in Q2 FY 2026-2027 from 16 in FY 2025-2026; cash and liquid investments of Rs.348 Cr as of 30 September 2026, up from Rs.203 Cr as of 31 March 2026.
• Interim dividend of Rs.1 per share declared — announced on the Q2 FY 2026-2027 call.
• Growth was not monsoon-dependent — Q2 growth of ~16% came despite one of the weakest monsoons in over two decades (rainfall ~13% below normal), which made seasonal acute-disease demand (dengue, malaria, typhoid, viral fevers) sporadic.

Broad-Based Growth Across B2C, B2B, Specialty and Tier 3

• B2C revenue +17% YoY in Q2 and H1 FY 2026-2027 — patient volumes +13.5%, test volumes +11%; same-store growth of 10% at existing centers; 116 collection centers added in Q2 (700 net additions over the last 24 months).
• B2B revenue +15% YoY in Q2 FY 2026-2027 — patient volumes +7% but test volumes +11% (more tests per patient, cited as growing wallet share); partner network crossed 9,000 partners.
• Specialty and True Health both grew ~20% — specialty contributed 40% of revenue and True Health 17% in Q2 FY 2026-2027; 43 specialty/super-specialty tests added in H1 FY 2026-2027; radiology-inclusive packages gaining traction.
• Tier 3 markets growing ~20% and contributing 26% of domestic revenue — as of Q2 FY 2026-2027, with contribution gradually rising; demand from both routine/semi-special tests and specialty tests routed to reference labs.
• North India now ~17% of domestic revenue — lifted by Core, Dapik (Dehradun) and Scientific (Agra); north zone grew 12% in Q2 FY 2026-2027 and ~16% in H1 FY 2026-2027 (the fastest-growing region on an H1 basis); West markets grew 16-17% in Q2.
• Patient volume growth accelerated to ~10% in Q2 FY 2026-2027 — from ~7% a year back (FY 2025-2026) and ~5% in Q4 FY 2025-2026; drivers are maturing tier 2/3 centers and customer lifecycle management/digital platform engagement driving repeat usage.
• Acquisitions performing — Dapik and Scientific grow in line with the company average at above-company margins; Core Diagnostics, break-even at acquisition ~1.5 years ago, now delivers double-digit margin in Q2 FY 2026-2027 with IRR ~13% over the past year, expected to accelerate in H2 FY 2026-2027.

First Price Hike in Two Years; Structural Margin Levers

• First price increase in two years is going ahead in FY 2026-2027 — MD Surendra Chaman Patel cited cost inflation across logistics, transportation and service costs; the one-year pause was solely because a newly applicable GST law gave input tax benefit and the company held back to remain tax-compliant.
• B2C price revision targeted early FY 2027-2028 — groundwork underway, with full pricing working expected within 4-6 weeks (~Q3 FY 2026-2027); revisions will differ across micro-markets, with estimated rollout in Q4 FY 2026-2027 for part of the business and no meaningful volume impact expected.
• Margin guidance for FY 2026-2027 — H1 delivered ~180-190 bps EBITDA margin expansion, with a similar trend (~180-200 bps alongside ~16% revenue growth) expected for the remainder of FY 2026-2027.
• ~125-150 bps annual margin improvement seen from FY 2027-2028 onward — management cited operating leverage, productivity initiatives and price revisions (yet to commence), net of parallel investments; expansion of ~25 mini hubs and retail product efforts may cost a little more.
• Lab platform transition closes by end of Q3 FY 2026-2027 — common test menu, equipment, reagents, TAT and vendor consolidation; full benefits accrue from Q4 FY 2026-2027 onward; center-to-lab ratio targeted at ~1:30 by end of FY 2026-2027 and over 35 by end of FY 2027-2028 (from 24:1), with no new labs being added across a 750-town footprint.
• Capex guided at 4-5% of revenue for FY 2026-2027 — same range as FY 2025-2026; normal all-in capex about Rs.65-70 Cr, with the same range expected in FY 2026-2027.

NMC Clarity a Tailwind; Pharma Price Caps Don't Touch Diagnostics

• Government price caps target hospital drug/consumable pricing, not diagnostics — management stated these measures have no bearing on Metropolis financially or operationally, with no move toward price capping or price parity in the diagnostics segment.
• New NMC clarification on remote report authorization is pan-India — Ameera Shah confirmed it spells out what can and cannot be done, enabling specialist pathologists in Bombay to approve reports in smaller markets like Patna; management expects faster mini-lab rollout in rural/tier-3 markets, better turnaround times and round-the-clock reporting; the earlier NMC-plus-state framework lacked clarity, with some states debating whether remote authorization was allowed.
• Mandatory display of rates is a "welcome change" — Metropolis already operates under upfront disclosure; management believes it narrows the information gap opaque, unorganized players rely on and favors organized, accredited players; similarly on the Maharashtra government directive requiring hospitals to publicly report procedure pricing, Metropolis is willing to publish rates across its centers and website.
• On hospital B2B outsourcing, management is in "wait and watch" mode — MD Surendra Patel said Metropolis's hospital contracts are at fixed discounted prices and any cap would apply to what hospitals charge customers; he said it is unlikely hospitals will outsource additional tests since most large hospitals have already set up their own labs; Ameera Shah said it is too early to say whether oncology changes are impacting hospital margins.
• Unorganized-to-organized shift seen as gradual, not a "hockey stick" — Ameera Shah cited COVID as a past trigger, when only 2,000 of ~300,000 labs in India received COVID-testing approval, and noted even well-funded organized entrants of the last 7-8 years have shut down after failing to scale profitably.

Insta60 Rollout, Genomics, AI and Asset-Light Bets

• Insta 60-minute home visit service scaling — launched in Mumbai with close to 100% of requested 60-minute visits fulfilled, then Chennai; Bangalore launch planned for the first week of November (Q3 FY 2026-2027); management does not expect the channel to cost more given omnichannel resource sharing.
• Genomics and oncology to be a "considerable portion" of the specialty portfolio — genomics is ~1.5-2 years old; Ameera Shah expects both portfolios to accelerate faster than average company growth, with significant acceleration in genomics over the coming years (no numeric target given).
• AI deployment across the value chain — sample logistics, lab operations, report validation and customer engagement; H2 FY 2026-2027 technology roadmap includes a new CRM platform, dynamic pricing engine, new field sales app and enhanced HLIMS/hospital portal integration, plus an end-to-end finance process re-engineering program.
• Asset-light investments committed over Q3-Q4 FY 2026-2027 — to potentially create a second growth engine besides pathology; a few ancillary services in preventive healthcare are being piloted, with updates as pilots progress; preventive healthcare revenues growing ~20% per year (current FY 2026-2027 run-rate).
• Disciplined M&A stance — management passed on deals at 18-20x EBITDA entry multiples where IRR works out to less than 10%, preferring value creation over 3 years generating IRR closer to 20%; it will continue evaluating M&A in North India across pathology and ancillary services, prioritizing IRR over buying revenue; no major acquisition plans for FY 2026-2027.
• Partner retention improved — Metlink partner portal live for ~18 months; partner churn now in low single digits versus close to double digits historically.

H2 Priorities and Watch Items

• ~16% revenue growth and 180-200 bps margin growth expected for the rest of FY 2026-2027 — MD Surendra Chaman Patel responding to JM Financial; management also expects strong margin expansion to continue in H2 FY 2026-2027 and over the next few years.
• H2 FY 2026-2027 priorities — accelerated center additions around newer labs, faster specialty-led B2B partner additions, ~25 mini hubs for closer-to-patient testing with basic radiology/allied services, higher retail/center productivity, and continued tier 2/3 focus with an accelerating pace of tier 2/3/4 center additions.
• Tests-per-patient optics flagged — the ~2 tests-per-patient metric reflects counting methodology (each True Health package counted as one test despite up to 50-60 parameters), not flat test mix; True Health is growing ~20% in Q2 FY 2026-2027.
• CGHS rate revision supported growth for several sector players, but Metropolis's CGHS revenue contribution is minimal — its growth is purely volume- and mix-based.
• Management declined to quantify Mumbai market share, citing no credible data, and suggested comparing competitor growth rates instead.
• Next interaction scheduled at end of Q3 FY 2026-2027 / early Q4 FY 2026-2027.